UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2022

CATALYST BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)

Delaware	**000-51173**	**56-2020050**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

611 Gateway Blvd, Suite 710, South San Francisco, CA 94080
(Address of principal executive offices)

(650) 871-0761
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	**CBIO**	**Nasdaq**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 12, 2022, Catalyst Biosciences, Inc. (the "Company") posted an update to its corporate presentation (the "Presentation") on its website, ir.catalystbiosciences.com/presentations-events. A copy of the Presentation is attached hereto as Exhibit 99.1.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Current Report shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Presentation slide deck.
104	Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CATALYST BIOSCIENCES, INC.

Date: January 12, 2022

/s/ Nassim Usman
Nassim Usman, Ph.D.
President and Chief Executive Officer

CATALYST BIOSCIENCES

Corporate Overview

12 January 2022

Forward looking statements

Certain information contained in this presentation and statements made orally durin
statements that involve substantial risks and uncertainties. All statements included i
historical facts, are forward-looking statements. This press release contains forwarc
risks and uncertainties. Forward-looking statements include, without limitation, our p
complement programs, our plans to continue to support Biogen in the development
complement has broad potential, can be combined with conventional therapies and
settings, as well as statements about the benefits of our protease engineering platfo

Actual results or events could differ materially from the plans, intentions, expectatio
looking statements. Various important factors could cause actual results or events t
the risk that clinical trials and preclinical studies may be delayed as a result of COV
that Biogen could terminate our agreement for the development of CB 2782-PEG, t
human clinical trials and will require additional manufacturing validation and preclini
that we may need to raise additional capital, and other risks described in the "Risk F
10-K filed with the Securities and Exchange Commission (the "SEC") on March 4, 2
with the SEC on November 12, 2021, and in other filings filed from time to time with
update any forward-looking statements, except as required by law.

Modulating Biological Systems w
Nature's Regulatory Proteins

- Proteases are nature's key regulatory proteins
- Innovative engineered molecules to degrade or activate therapeutic targets
- Applicable across multiple disease areas

We harness the regulatory power of prote

Catalyst's protease platform in compleme

Validated across three programs

CB 2782-PEG Biogen

Best-in-class profile for dry AMD
Extended pharmacodynamics



Novel C3-degrader for dry AMD

CB 4332 PK extended (

Restoring balance to comple
where CFI activity is insuffici



Unique targeted approach to complement



Catalyst protease and protein degrader di

Distinct expertise enables design of optimal therap



Nature’s way to regulate complement

A platform based on the natural braking mechanism



- Rebalances complement usi
  natural brakes (CFI)
- Multiple diseases driven by
  deposition & immune activat
- Differentiated mechanisms t
  regulate at or around C3 & C
- Safely regulate complement
  broad immunosuppression
- Uses the natural regulatory
  to modulate the complement

Nature's way to regulate complement

A platform based on the natural braking mechanism



Our protease platforms are tailored to spe

Tuning functionality to restore complement homeos



Specific inhibition of complement components at different si
allows a personalized approach to treating complement disc

CB 4332

Half-Life Extended Complement Factor I to rebalance the complement system



CB 4332: Extended half-life Complement F

Development candidate to restore regulation



+ **Engineered for an extended half-life**
  + Potential for once weekly SQ therapy
+ ***In vitro & ex vivo* activity comparable to native CFI**
  + Classical & alternative pathway regulation
+ **High yield production process**
+ **Safe GLP toxicology with a high dosing window**
+ **Entering the clinic in 2022**

 [1]Bienaime *et al*. Kidney Int. (2010); [2]Ferreira *et al.* Nefrologia. (2016); Note: CFI = Complement fact

Systemic & ocular CFI to rebalance the co

CB 4332 has potential to address a breadth of mech



*Patient population estimate *does not include age-related macular degeneration US population with rare CFI variants*
AMD: Age-Related Macular Degeneration, aHUS: atypical Hemolytic Uremic Syndrome, C3G: C3 Glomerulonephropathy, SL
AIHA: Autoimmune Hemolytic Anemia, ANCA: ANCA-associated Vasculitis, ITP: Immune Thrombocytopenia, HAE: Hereditar

CB 4332 may target diseases of excessive C3b

Deposition of C4b & C3b in AIHA lead to hemolysis



C3b & C4b Degraders

Broad applications in complement-mediated disorders



Improved catalytic power & specificity for

ProTUNE™ platform has been used to generate spe



Using ProTUNE™ Platform to tune C3b & C4b



Cofactor independent CFI may target patie

ProTUNE™ platform has generated degraders that







Cofactor independent m
of addressable patients

C3b & C4b degraders significantly reduce

Rat sepsis model of complement activation

Reduction of **IFNγ, TNFα,** and **RAN**
chemokines involved in kidney dam
proteinuria in IgA nephropathy patie

Concomitant reduction of inflammatory markers and complement C3 cleavage





Inflammatory markers in IgA nephropathy





Example: C3b/C4b degraders for IgA neph

Disease in which both lectin & alternative pathways

High unmet need – current treatments only address sym

- Most common form of glomerulopathy with accumulation & deposition of IgA immune complexes deteriorating renal function
- patients with rapidly progressive glomerulonephritis
- of IgAN patients develop end stage renal disease over 20 years & need dialysis/renal transplant in order to survive
- will modulate the alternative & lectin pathways to address complement dysregulation with low off-target effects
- Significant burden on healthcare resources with an estimated cost of in 2020 in the US

Example: C3b/C4b degraders for IgA neph

Dual targeting of alternative & lectin pathways



[1]Medjeral-Thomas et al. Kidney International Reports (2018); [2]Bi et al. BMC Nephrology (2019);

C3a & C5a Degraders

For inflammatory disorders

Dialing catalytic power & specificity to restore

Using the ImmunoTUNE™ engineering platform to tu



C3a/C5a degraders: Efficacy in acute LPS-i

Improves respiratory function & reduces cell infiltra

Respiratory functions & cell infiltration at 24 h





CFx 7-fold lower dose vs. anti-C5

Mou

- CB 6000 **outperforms** anti-C5 antibody[1] in reducing infla
- CB 6000 **compares well** on respiratory functions with ar

[1]Mouse surrogate of Solaris (BB5.1)

Example: C3a/C5a degraders: Potential for ANC

Autoimmune disease where anaphylatoxins play a r



High unmet need – current treatme

- Autoimmune disorder characterized by blood vessels
- Clinical signs vary & affect several orga upper respiratory track & kidneys
- Severe pain due to neuropathy, pulmon
- of patients die within the 1st year of trea conventional therapies (immunosuppres
- The only treatments available are to ma

[1]S. Moiseev et al. British Society for Immunology, Clinical and Experimental Immunology (2020)

Example: C3a/C5a degraders: Potential for ANC

Dual targeting of both C3a & C5a with one protease



+ Bc as

+ De C5

+ Ur fur

+ Inh in

[1]S. Moiseev et al. British Society for Immunology, Clinical and Experimental Immunology (2020)



CB 2782-PEG

Novel engineered C3 degrader

Partnered with Biogen

Complement inhibition is a validated appr



Drug	Cate
GT005	CFI ther
Pegcetacoplan	PEG amir cycl pept
NGM621	Anti anti-
Zimura	pegy RNA apta
CB 2782-PEG (Preclinical)	PEG anti- prot

CB 2782-PEG: Best-in-class C3 degrader f

The protease advantage demonstrated *in vivo*



Cataly

+ One
+ Fast
+ Exte
+ Can
+ Engi
  awa

Catalyst Biosciences protease platform ha

Building on nature's way of regulating key processe

- Catalyst develops enhanced **natural core proteases** & **complement regulation**
- Catalyst has designed optimized, next-generation **comp**
- Complement dysregulation serves as **driver** for many di
- Catalyst has **protease programs** designed to take adva complement regulators that **restore complement home complement-mediated disorders**
- Application of Catalyst's protease & protein degrader tec in **immunology, nephrology, hematology, ocular dise**

Overview of complement portfolio

Multiple value generating events in 2022 & 2023



THANK YOU

www.CatalystBiosciences. com